Literature DB >> 11086116

Utilizing fowlpox virus recombinants to generate defective RNAs of the coronavirus infectious bronchitis virus.

Sharon Evans1, David Cavanagh1, Paul Britton1.   

Abstract

Coronavirus defective RNAs (D-RNAs) have been used as RNA vectors for the expression of heterologous genes and as vehicles for reverse genetics by modifying coronavirus genomes by targetted recombination. D-RNAs based on the avian coronavirus infectious bronchitis virus (IBV) D-RNA CD-61 have been rescued (replicated and packaged into virions) in a helper virus-dependent manner following electroporation of in vitro-generated T7 transcripts into IBV-infected cells. In order to increase the efficiency of rescue of IBV D-RNAs, cDNAs based on CD-61, under the control of a T7 promoter, were integrated into the fowlpox virus (FPV) genome. The 3'-UTR of the D-RNAs was flanked by a hepatitis delta antigenomic ribozyme and T7 terminator sequence to generate suitable 3' ends for rescue by helper IBV. Cells were co-infected simultaneously with IBV, the recombinant FPV (rFPV) containing the D-RNA sequence and a second rFPV expressing T7 RNA polymerase for the initial expression of the D-RNA transcript, subsequently rescued by helper IBV. Rescue of rFPV-derived CD-61 occurred earlier and with higher efficiency than demonstrated previously for electroporation of in vitro T7-generated RNA transcripts in avian cells. Rescue of CD-61 was also demonstrated for the first time in mammalian cells. The rescue of rFPV-derived CD-61 by M41 helper IBV resulted in leader switching, in which the Beaudette-type leader sequence on CD-61 was replaced with the M41 leader sequence, confirming that helper IBV virus replicated the rFPV-derived D-RNA. An rFPV-derived D-RNA containing the luciferase gene under the control of an IBV transcription-associated sequence was also rescued and expressed luciferase on serial passage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086116     DOI: 10.1099/0022-1317-81-12-2855

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Reverse genetics system for the avian coronavirus infectious bronchitis virus.

Authors:  R Casais; V Thiel; S G Siddell; D Cavanagh; P Britton
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Gene 5 of the avian coronavirus infectious bronchitis virus is not essential for replication.

Authors:  Rosa Casais; Marc Davies; David Cavanagh; Paul Britton
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Neither the RNA nor the proteins of open reading frames 3a and 3b of the coronavirus infectious bronchitis virus are essential for replication.

Authors:  Teri Hodgson; Paul Britton; Dave Cavanagh
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  In vitro and in ovo expression of chicken gamma interferon by a defective RNA of avian coronavirus infectious bronchitis virus.

Authors:  Karen Hackney; Dave Cavanagh; Pete Kaiser; Paul Britton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Modification of the avian coronavirus infectious bronchitis virus for vaccine development.

Authors:  Paul Britton; Maria Armesto; David Cavanagh; Sarah Keep
Journal:  Bioeng Bugs       Date:  2012-03-01

6.  Presence of an encephalomyocarditis virus internal ribosome entry site sequence in avian infectious bronchitis virus defective RNAs abolishes rescue by helper virus.

Authors:  Brian Dove; David Cavanagh; Paul Britton
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Generation of a recombinant avian coronavirus infectious bronchitis virus using transient dominant selection.

Authors:  Paul Britton; Sharon Evans; Brian Dove; Marc Davies; Rosa Casais; Dave Cavanagh
Journal:  J Virol Methods       Date:  2005-02       Impact factor: 2.014

8.  Rapid Recovery of Classical Swine Fever Virus Directly from Cloned cDNA.

Authors:  Jun-Hua Huang; Yong-Feng Li; Fan He; Dan Li; Yuan Sun; Wen Han; Hua-Ji Qiu
Journal:  J Integr Agric       Date:  2013-05-08       Impact factor: 2.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.